United States
Environmental Protection Agency
Office of Prevention, Pesticides and Toxic Substances
(7505P)

**\$EPA** 

# Pesticide Fact Sheet

Name of Chemical: Mammalian Gonadotropin

**Releasing Hormone (GnRH)** 

**Reason for Issuance:** New Chemical

**Nonfood Use** 

Date Issued: September 2009

\_\_\_\_\_

## 1. Description of Chemical

Peptide Chain: pyroGlu1 -His2-Trp3- Ser4 -Tyr5- Gly6 -Leu7-Arg8-

Pro9- G ly10NH2 [GnRH]

Common Name: Mammalian Gonadotropin Releasing Hormone (GnRH)

EPA PC Code: 116800

**Chemical Abstracts** 

Service (CAS) Number: 9034-40-6

Chemical Class: Sterilant/Hormone

Registration Status: New Chemical, nonfood use

Pesticide Type: Mammalian Contraceptive

U.S. Producer: U.S. Department of Agriculture, APHIS, Pocatello

Supply Depot

238 East Dillon Street Pocatello, ID 83201

## 2. Use Pattern and Formulations

Mode of Action The active ingredient, Mammalian Gonadotropin Releasing

Hormone (GnRH) is conjugated into a large protein that initiates an immune response in the animal with its own GnRH resulting in contraceptive effects for a minimum of one year.

Application Sites GonaCon will be used to control wild white-tailed deer

Odocoileus virginianus) populations in areas where they have

become a nuisance (e.g, urban and suburban settings).

Methods of Application

The vaccine will be administered to restrained female deer using preloaded syringes with an 18 or 19 gauge stainless steel hypodermic needle intramuscularly into a large muscle mass by

hand injection only.

GonaCon is classified as a Restricted Use Pesticide. Use is restricted to USDA APHIS Wildlife Services or state wildlife

management personnel or persons working under their

authority.

Application Rate: Female deer are injected with a single injection containing 1.0

ml of GonaCon at least two to three months prior to the onset of rut for full contraceptive effect. If multi year contraceptive effects are desired, a second vaccination may be given 30 to 60 days after the first injection or during the following year.

Two formulations (basic and alternate) are proposed for

registration.

## 3. Science Findings

Available data supporting the use and registration of Mammalian Gonadotropin Releasing Hormone including product chemistry, toxicology, efficacy, and ecological effects and environmental fate are summarized below.

<b>Table 1. Product Chemistry</b>	Summary
Peptide structure	PCN-1  HNS-2  TRyR-3  SER-4  GEN-10  PRIO-9  AM8-8
Common name	Mammalian Gonadotropin Releasing Hormone (GnRH)
CAS Reg. No.	9034-40-6
Color	white
Physical State	Active: solid: powder EU: liquid: somewhat creamy in appearance
Melting Point	N/A Waiver request
Boiling Point	Waiver request: Solid at room temperature.
Odor	Active: odorless EU: odorless
Stability to Normal and Elevated Temperatures, Metal, and Metal Ions	N/A Waiver request
Oxidation/Reduction Action	N/A Waiver request
pН	Active: NA EU: pH = 6.49
Flammability	N/A Waiver request
Explodability	N/A Waiver request
Vapor pressure	N/A Waiver request
Water Solubility	N/A Waiver request
Storage stability	N/A product's shelf life will be $\leq$ 6 months so not necessary
Corrosion Characteristics	N/A product's shelf life will be $\leq 6$ months so not necessary

#### **TOXICOLOGY SUMMARY**

The Registrant submitted the studies listed in Tables 2, which include a number of toxicity studies. The Registrant submitted waiver requests which were granted for acute inhalation and dermal sensitization.

#### **Acute Toxicity Data GnRH**

Table 2. Acute 7	Table 2. Acute Toxicity				
Guideline No.	Study Type	Results	Toxicity Category*		
OPPTS 870.1100	Acute Oral Rat	All test animals survived 1 mL exposure.	IV		
OPPTS 870.1200	Acute Dermal Rat	All test animals survived 1 mL exposure.	IV		
OPPTS 870.1300	Acute Inhalation Rat	WAIVED	IV		
OPPTS 870.2400	Primary Eye Irritation Rabbit	No corneal opacity or iritis was observed. 1-hour post-instillation: 3/3 treated eyes exhibited conjunctival redness (score 1-2) and discharge (score 1). No "positive" grade irritation was noted at the 24-hour observation. Treated eyes were free of all eye irritation by 72-hours.	IV		
OPPTS 870.2500	Primary Skin Irritation Rabbit	No edema was observed at any treated site. Very slight erythema (score 1) was noted at all 3/3 test sites within 1-hour post-pad removal. Irritation severity decreased thereafter. No irritation was noted at the 72-hour observation. The PDII was 0.5.	IV		
OPPTS 870.2600	Dermal sensitization	WAIVED			

• Toxicity Category IV = No precautions required

Chronic toxicity data requirements were waived. There is no human exposure from use of GonaCon, therefore no toxicity endpoints were selected because of the very limited potential worker and dietary exposure.

#### **ECOLOGICAL EFFECTS**

Waivers were submitted to fulfill required ecological effects and environmental fate guideline studies for the registration of GonaCon because of the limited potential for environmental releases. Since the product is labeled only for injection to deer by hand and the substance is expected to be rapidly metabolized in treated animals, the limited

potential risks to non-target organisms resulting from the proposed registration of GonaCon are not expected to exceed the Agency's concern levels.

The proposed registration of GonaCon is expected to have no effect on endangered or threatened species

#### **EFFICACY**

GonaCon is intended to render a vaccinated female white-tailed deer infertile for a minimum of one year following vaccination. GonaCon is not expected to affect existing pregnancies but should cause infertility of the vaccinated animal in subsequent years. If multi-year contraceptive effects are desired, a second vaccination may be given 30-60 days after the first injection or during the following year. There is a chance that some vaccinated females will become permanently sterile.

Product performance studies were conducted by APHIS's National Wildlife Research Center (NWRC) both in the field over a two year period and in a laboratory over multiple years to compare two different formulations.

The field test, initiated in 2004 used two sites consisting of fenced federal land near Silver Spring, MD. Female deer in the vaccinated group were dosed with the labeled rate of the vaccine during July and August 2004. All deer were marked with ear tags and radio telemetry collars equipped with mortality sensors. Reproductive status was assessed in the summers of 2005 and 2006 with visual inspection of the udders for signs of lactation.

Results showed 88% efficacy in the summer after vaccination with lactation evident in 3 of the 26 does vaccinated (12%). Of the control group, reproductive status was able to be determined in 13 of the 15 deer and lactation was evident in 11 of those 13 doe (85%).

In the second summer after vaccination lactation was evident in 10 of the remaining 19 vaccinated deer (53%) equating to an efficacy rate of 47%. In the control group, 10 of the 10 remaining deer (100%) had reproductive success.

The lab study results showed the alternate formulation to be more effective than the basic formulation. The alternate formulation had a 100% success rate (5/5 does remained contracepted for two years) compared to the basic formulation with a 60% success rate after two years (3/5 does contracepted). Due to economic and supply reasons however, it is necessary for the product to carry both formulations.

## 4. Summary of Regulatory Position and Rationale

Available data provide adequate information to support the conditional registration of GnRH as a tool for management of nuisance white-tailed deer.

White-tailed deer have been classified by EPA as a public health pest because they are a host for blacklegged ticks (*Ixodes scapularis*), more commonly known as deer ticks, which are a carrier of Lyme disease.

In many urban and suburban areas white-tailed deer populations have become over abundant and are considered a year-round nuisance causing many human-wildlife conflicts such as destruction on gardens, landscapes and golf courses as well as a cause of numerous vehicle accidents. According to a 2006 study, the National Highway Traffic Safety Administration reported that there are about 1.5 million car accidents with deer resulting in over \$1 billion of damage and 150 human fatalities annually.

GonaCon is intended to be used in combination with other management techniques since it cannot alone reduce already over abundant populations.

## **5. Labeling Restrictions**

To mitigate any risks, the following requirements have been imposed:

- Restricted -Use Pesticide classification due to non-target injection hazard.
- Application is restricted to USDA APHIS Wildlife Services or state wildlife management agency personnel or persons working under their authority only.
- Administration of vaccine is only by hand injection to mitigate any non-target or environmental risks that occur with administration with darts.
- Use restricted to only one species: white-tailed deer (*Odocoileus virginianus*).
- PPE requirements include: long sleeved shirt and long pants, gloves and shoes plus socks to mitigate occupational exposure.
- Children are not allowed in areas where product is used
- A warning that pregnant women should not be involved in handling or injecting GonaCon and that all women should be aware that accidental self-injection may cause infertility.

## **6. Conditional Data Requirements**

Because of the unique chemical nature of GnRH additional preliminary analysis and certified limits data are necessary. The registrant must submit this data to the Agency upon completion.

Conditional data required for GonaCon consists of:

- Guideline 830.1700 Validating the method of analysis of the formulation and additional preliminary analysis
- Guideline 830.1750 Certified Limits

#### **Contact Person at USEPA**

#### **Mailing address:**

Autumn Metzger Biologist, Insecticide-Rodenticide Branch Environmental Protection Agency Office of Pesticide Programs Registration Division (7505P) Insecticide Branch 1200 Pennsylvania Avenue NW Washington, D.C. 20460

#### Office location and telephone number:

Room S-7224, One Potomac Yard 2777 S. Crystal Drive Arlington, VA 22202 703-305-5314

DISCLAIMER: The information in this Pesticide Fact Sheet is for information only and is not to be used to satisfy data requirements for pesticide registration. The information is believed to be accurate as of the date on the document.

#### APPENDIX I

#### GLOSSARY OF TERMS AND ABBREVIATIONS

ADNT Acute delayed neurotoxicity

a.i. Active Ingredient

aPAD Acute Population Adjusted Dose

ARI Aggregate Risk Index
BCF Bioconcentration Factor
CAS Chemical Abstracts Service

ChE Cholinesterase

ChEI Cholinesterase inhibition

cPAD Chronic Population Adjusted Dose

%CT Percent crop treated DAT Days after treatment

DEEM-FCID Dietary Exposure Evaluation Model - Food Consumption Intake Database

DNA Deoxyribonucleic acid
DNT Developmental neurotoxicity
DIT Developmental immunotoxicity

DWLOC Drinking Water Level of Comparison. EC Emulsifiable Concentrate Formulation

EEC Estimated Environmental Concentration. The estimated pesticide

concentration in an environment, such as a terrestrial ecosystem.

EPA U.S. Environmental Protection Agency

FQPA Food Quality Protection Act GLC Gas Liquid Chromatography

GLN Guideline Number

LC<sub>50</sub> Median Lethal Concentration. A statistically derived concentration of a

substance that can be expected to cause death in 50% of test animals. It is usually expressed as the weight of substance per weight or volume of

water, air or feed, e.g., mg/l, mg/kg or ppm.

LD<sub>50</sub> Median Lethal Dose. A statistically derived single dose that can be

expected to cause death in 50% of the test animals when administered by the route indicated (oral, dermal, inhalation). It is expressed as a weight of

substance per unit weight of animal, e.g., mg/kg.

LOAEL Lowest Observed Adverse Effect Level

LOAEC Lowest Observed Adverse Effect Concentration

LOC Level of Concern
LOD Limit of Detection
LOQ Limit of Quantitation

mg/kg/day Milligram Per Kilogram Per Day

mg/L Milligrams Per Liter MOE Margin of Exposure

MRID Master Record Identification (number), EPA's system of recording and

tracking studies submitted

MTD Maximum tolerated dose

NA Not Applicable

NOEC No Observable Effect Concentration

NOEL No Observed Effect Level

NOAEL No Observed Adverse Effect Level

NOAEC No Observed Adverse Effect Concentration
NPDES National Pollutant Discharge Elimination System

OP Organophosphate

OPP EPA Office of Pesticide Programs

OPPTS EPA Office of Prevention, Pesticides and Toxic Substances

PAD Population Adjusted Dose
PAG Pesticide Assessment Guideline
PAM Pesticide Analytical Method
PHED Pesticide Handler's Exposure Data

PHI Preharvest Interval ppb Parts Per Billion

PPE Personal Protective Equipment

ppm Parts Per Million

PRZM/EXAMS Tier II Surface Water Computer Model

RAC Raw Agriculture Commodity

RBC Red Blood Cell

RED Reregistration Eligibility Decision

REI Restricted Entry Interval

RfD Reference Dose

SCI-GROW Tier I Ground Water Computer Model

SF Safety Factor

TGAI Technical Grade Active Ingredient

UF Uncertainty Factor

μg micrograms

 $\mu g/L$  Micrograms Per Liter  $\mu L/g$  Microliter per gram

USDA United States Department of Agriculture

WPS Worker Protection Standard

## APPENDIX II

## Citations Considered Part of the Data Base Supporting the Registration of ${\bf GonaCon.}$

MRID	Citation	Receipt Date
47649600	United States Department of Agriculture's Animal and Plant Health Inspection Service (USDA APHIS) (2009) Submission of Product Chemistry, Toxicity, Efficacy and Residue Data in Support of the Application for Registration of GonaCon Immunocontraceptive Vaccine. Transmittal of 36 Studies.	22-Jan- 2009
47649601	O'Hare, J.; Eisemann, J. (2008) Description of Materials Used to Produce: "GoneCon Immunocontraceptive Vaccine". Project Number: P4417. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 168 p.	22-Jan- 2009
47649602	O'Hare, J.; Eisemann, J. (2008) Description of Formulation Process Used to Manufacture: "GonaCon Immunocontraceptive Vaccine". Project Number: M8546, BT016/02. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 99 p.	22-Jan- 2009
47649603	O'Hare, J.; Pilon, J.; Eisemann, J. (2008) Discussion of the Formation of Impurities "GonaCon Immunocontraceptive Vaccine". Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlive Research Center. 56 p.	22-Jan- 2009
47649604	O'Hare, J.; Eisemann, J.; Pilon, J. (2008) Preliminary Analysis and Certified Limits "GonaCon Immunocontraceptive Vaccine": Final Report. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 9 p.	22-Jan- 2009
47649605	O'Hare, J.; Eisemann, J. (2008) Enforcement Analytical Method: "GonaCon Immunocontraceptive Vaccine". Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 40 p.	22-Jan- 2009
47649606	O'Hare, J.; Eisemann, J. (2007) Product Chemistry: Color, Physical State, Odor, and pH - USDA APHIS GonaCon Immunocontraceptive Vaccine (EPA Reg. No. 56228-xx): Final Report. Project Number: QA/1421. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 31 p.	22-Jan- 2009
47649607	Warren, J.; Stephens, S. (2008) Stability to Normal and Elevated Temperatures, Metal, and Metal Ions: (Gonadotropin Releasing Hormone). Unpublished study prepared by US Dept. of Agriculture, APHIS, WS. 8 p.	22-Jan- 2009
47649608	Warren, J.; Stephens, S. (2008) Oxidation/Reduction Chemical Incompatibility: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by US Dept. of Agriculture, APHIS, WS. 8 p.	22-Jan- 2009
47649609	Warren, J.; Stephens, S. (2008) Flammability: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009

47649610	Warren, J.; Stephens, S. (2008) Explodability: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649611	Warren, J.; Stephens, S. (2008) Miscibility: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649612	Warren, J.; Stephens, S. (2008) Corrosion Characteristics: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649613	Warren, J.; Stephens, S. (2008) Dielectric Breakdown Voltage: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649614	Warren, J.; Stephens, S. (2008) UV/Visible Absorption: (GonaCon Immunocontraceptive). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649615	Warren, J.; Stephens, S. (2008) Viscosity: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649616	Warren, J.; Stephens, S. (2008) Melting Point: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649617	Warren, J.; Stephens, S. (2008) Boiling Point: (GonoCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649618	Warren, J.; Stephens, S. (2008) Density/Relative Density/Bulk Density: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649619	Warren, J.; Stephens, S. (2008) Dissociation Constant in Water: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649620	Warren, J.; Stephens, S. (2008) Octanol/Water Partition Coefficient: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649621	Warren, J.; Stephens, S. (2008) Water Solubility: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649622	Warren, J.; Stephens, S. (2008) Vapour Pressure: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 8 p.	22-Jan- 2009
47649623	Eisemann, J.; O'Hare, J. (2008) Chemical Identity: "GonaCon Immunocontraceptive Vaccine". Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: Natiional Wildlife Research Center. 27 p.	22-Jan- 2009
47649624	Eisemann, J.; O'Hare, J. (2008) Direction for Use: GonaCon Immunocontraceptive Vaccine. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Research Center. 12 p.	22-Jan- 2009
47649625	Lowe, C. (2008) GonaCon Immunocontraceptive Vaccine: Acute Oral	22-Jan-

	Toxicity - Limit Dose Procedure in Rats. Project Number: P320/USDA, 23211. Unpublished study prepared by Product Safety Laboratories. 28 p.	2009
47649626	Lowe, C. (2008) GonaCon Immunocontraceptive Vaccine: Acute Dermal Toxicity - Limit Dose Procedure in Rats. Project Number: 23212, P322/USDA. Unpublished study prepared by Product Safety Laboratories. 28 p.	22-Jan- 2009
47649627	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Acute Inhalation Toxicity: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649628	Lowe, C. (2007) GonaCon Immunocontraceptive Vaccine: Primary Eye Irritation Study in Rabbits. Project Number: P324, 22806. Unpublished study prepared by Product Safety Laboratories. 29 p.	22-Jan- 2009
47649629	Lowe, C. (2008) GonaCon Immunocontraceptive Vaccine: Primary Skin Irritation Study in Rabbits. Project Number: P326, 22807. Unpublished study prepared by Product Safety Laboratories. 27 p.	22-Jan- 2009
47649630	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Dermal Sensitization: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649631	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Chronic Dietary Toxicity: (GonaCon Immunocontraceptive Vaccine). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649632	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Gene Mutation: (GonaCon Immunocontraceptive Vaccine): (Human). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649633	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Stuctural Chromosomal Aberration: (GonaCon Immunocontraceptive Vaccine): (Human). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649634	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Other Genotoxic Effects: (GonaCon Immunocontraceptive Vaccine): (Human). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649635	O'Hare, J.; Eisemann, J.; Stephens, S. (2008) Acute Delayed Neurotoxicity: (GonaCon Immunocontraceptive Vaccine): (Hen). Unpublished study prepared by USDA APHIS. 4 p.	22-Jan- 2009
47649636	Gionfriddo, J.; Eisemann, J.; O'Hare, J. (2008) Product Performance: Field Test of a Single-Injection of GonaCon Immunocontraceptive Vaccine In Female White-Tailed Deer. Project Number: QA/1112. Unpublished study prepared by US Dept. of Agriculture, APHIS, WS: National Wildlife Research Center. 31 p.	22-Jan- 2009